Regeneron Pharmaceuticals: A Deep Dive Into Bear’s Perspective! 

Regeneron Pharmaceuticals reported substantial growth in its second quarter of 2024, with a 12% increase in total revenues to $3.55 billion. This rise was driven significantly by the U.S. sales of EYLEA HD, which reached $304 million in its third quarter on the market. The combined net product sales of EYLEA HD and EYLEA were $1.53 billion, marking a 2.3% year-over-year growth. A significant highlight was the strong performance of Dupixent, whose global revenues increased by 29% on a constant currency basis to $3.56 billion due to solid growth across various indications and demographics. In an important development, the European Commission approved Dupixent for Chronic Obstructive Pulmonary Disease (COPD) in patients with raised blood eosinophils, marking it the first regulatory approval for this indication.